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Introduction
Recent genetic studies have revealed a large number of risk 
genes for autism spectrum disorder (ASD). Many of these genes 
encode proteins important for synaptic development and func-
tion. One such gene is SH3 and multiple ankyrin repeat domains 3 
(SHANK3). SHANK3 is a member of the Shank family of proteins 
(SHANK1–3). SHANK proteins interact with various postsynap-
tic density (PSD) proteins through 5 main functional domains: 
N-terminal ankyrin repeats, SH3 domain, PDZ domain, proline-
rich region, and a C-terminal sterile α motif (SAM) (1–5). Most 
notably, SHANKs bind to synapse-associated protein 90/post-
synaptic density 95–associated protein (SAPAP, also known as 
GKAP or DLGAP), which in turn binds to PSD95 family proteins 
to form the PSD95/SAPAP/SHANK postsynaptic complex (2, 4, 
6, 7). These 3 groups of multidomain proteins are proposed as 
forming a key postsynaptic scaffold, playing an important role in 
targeting, anchoring, and dynamically regulating synaptic local-
ization of neurotransmitter receptors and signaling molecules (8). 
SHANKs are also connected to the metabotropic glutamate recep-
tor (mGluR) pathway through binding to Homer (9–11). In addi-
tion, given the SHANK protein’s link to actin-binding proteins, 
SHANKs have been shown to regulate spine development (10, 
12, 13). Thus, SHANK proteins have been proposed as playing key 
roles in synaptic development and function (11, 14, 15).
Disruption of SHANK3 is thought to be the cause of the core 
neurodevelopmental and neurobehavioral deficits in Phelan-
McDermid syndrome (PMS, 22q13.3 deletion syndrome), as indi-
viduals carrying a ring chromosome 22 with an intact SHANK3 
gene are phenotypically normal (16–22). PMS is a neurodevelop-
mental disorder characterized by intellectual disability, autistic-
like behaviors, hypotonia, and impaired development of speech 
and language (23, 24). Moreover, recent genetic studies have iden-
tified a large number of SHANK3 mutations in ASD patients not 
diagnosed with PMS (20, 25–28), strongly implicating SHANK3 
gene disruption or mutation as a monogenic cause of ASD (18, 20, 
23, 29, 30). In support of these genetic findings, Shank3 mutant 
mice exhibited various synaptic defects and ASD-related behav-
ioral abnormalities, including repetitive grooming behaviors and 
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sis is still lacking. In particular, it is not clear whether the direct 
and indirect pathways of the basal ganglia are differentially 
affected in Shank3B mutant mice.
For the current study, we performed a systematic character-
ization of synaptic transmission, synaptic plasticity, neuronal 
morphology in D1 and D2 MSNs as well as their role in repeti-
tive behaviors in the Shank3B mutant mouse model of ASD. We 
revealed both distinct and shared defects in these 2 primary 
subtypes of striatal neurons: D2 MSNs showed marked defects 
across all parameters examined, including pre- and postsynaptic 
synaptic function, synaptic plasticity, and spine density, while 
D1 MSNs only presented postsynaptic defects with a reduced 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid recep-
tor (AMPAR) response. Consistent with the more profound syn-
aptic defects in D2 MSNs in Shank3B mutant mice, the repetitive 
grooming behavior was corrected by selectively enhancing indi-
rect pathway activity, but not direct pathway, activity. Our find-
ings provide direct evidence of distinct changes between the 2 
striatal pathways in a mouse model of autism and highlight that 
indirect striatal pathway disruption might play a causative role 
in repetitive behavior.
Results
Shank3 deletion preferentially affects glutamatergic synaptic trans-
mission in striatopallidal MSNs. To specifically test whether dele-
tion of the Shank3 gene differentially affects synapses of D1 MSN 
and D2 MSNs, we crossed Shank3B-KO mice with transgenic mice 
social interaction deficits (31–36). Thus, Shank3 mutant mice pro-
vide us with a monogenic model for studying neural mechanisms 
underlying autism-relevant behaviors.
Dysfunction of the basal ganglia has been strongly impli-
cated in a variety of psychiatric disorders characterized by 
inflexible and maladaptive behaviors, such as obsessive and 
compulsive disorders (OCD), drug addiction, Tourette syn-
drome, and ASD (37–41). The dorsal striatum, the largest nucle-
us of the basal ganglia, receives converging information from 
cortex and thalamus to mainly control voluntary motor actions 
and procedural learning (42, 43). Output from the dorsal stria-
tum is organized into 2 primary projection pathways, dopamine 
D1 receptor expressing striatonigral neurons forming the direct 
projection pathway (D1 MSN, where MSN indicates medium 
spiny neuron) and D2 receptor expressing striatopallidal neu-
rons forming the indirect striatal projection pathway (D2 
MSN), respectively (44, 45). Instead of the opposing roles of 
the 2 pathways suggested in the classical model of basal ganglia 
circuitry, recent findings highlight that the cooperative, con-
current, and balanced activity of the 2 pathways is critical for 
motor control, action initiation, and selection (46–48). Our pre-
vious studies demonstrated that disruption of the Shank3 gene 
in mice resulted in both structural and functional defects in 
excitatory synapses of MSNs in the dorsal striatum (31, 49, 50). 
Although these striatal synaptic defects have been proposed to 
be the cause of repetitive and compulsive grooming behavior in 
Shank3B mutant mice, direct evidence to support this hypothe-
Figure 1. Differential effects of Shank3 deletion on glu-
tamatergic synaptic transmission in D1 and D2 MSNs. (A 
and B) Representative recording traces of AMPA-mediated 
mEPSCs of D1 MSNs (A) and D2 MSNs (B) in the presence of 
TTX (0.5 μM), PTX (100 μM), and DL-APV (50 μM) from acute 
striatal brain slices. (C and D) Summary data of mEPSC fre-
quency (C) and peak amplitude (pA) (D) from D1 MSNs and 
D2 MSNs of WT and KO mice (mEPSC frequency: WT D1,  
n = 17, N = 4, KO D1, n = 17, N = 4, P = 0.73. WT D2, n = 13, N = 3; 
KO D2, n = 13, N = 3, P = 0.0039; mEPSC amplitude: WT D1 
and KO D1, P = 0.053. WT D2 and KO D2, P = 0.006). (E) Rep-
resentative traces and summary data of PPR of D1 MSNs 
from WT and KO mice. (F) Representative traces and sum-
mary data of PPR of D2 MSNs from WT and KO mice (PPR: 
WT D1, n = 17, N = 4, KO D1, n = 18, N = 4, P = 0.67; WT D2,  
n = 15, N = 4, KO D2, n = 15, N = 4, P = 0.048). An unpaired  
t test was used for comparisons. *P < 0.05;  
**P < 0.01. n, cell number; N, animal number.
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act as retrograde signaling to activate presynaptically located CB1 
receptors (CB1Rs) to reduce neurotransmission. However, there 
is controversy in the literature as to whether the eCB-LTD can be 
induced at glutamatergic synapses onto both D1 and D2 MSNs 
because high-frequency electrical stimulation (eHFS) might 
recruit intrastriatal dopaminergic and cholinergic signaling that 
can modulate this form of LTD (56–60). We thus started out to 
test whether the induction protocol, pairing HFS (4 trains of 100 
Hz/s given at 10-second interval) of presynaptic glutamatergic 
afferent fibers by placing a stimulating electrode at the inner edge 
of the corpus callosum (instead of intrastriatal stimulation) and 
postsynaptic depolarization (DP) of MSNs (HFS/DP), was able 
to induce LTD in both types of MSNs and whether LTD could be 
blocked by a CB1R antagonist in both types of neurons. Consistent 
with previous reports (55, 56, 58, 61–63), the HFS/DP stimula-
tion paradigm led to the induction of robust LTD in WT D1 MSNs 
and D2 MSNs in the dorsal striatum, as evidenced by the reduc-
tion in the amplitude of evoked EPSCs (eEPSCs) (Figure 2). This 
reduction in eEPSC amplitude following LTD induction was also 
accompanied by an increase in PPR, which suggests a reduction 
in presynaptic glutamate release probability. In addition, as shown 
in Supplemental Figure 3, the LTD in both types of neurons can 
be blocked by AM251, a CB1R antagonist, suggesting that the LTD 
at both D1 and D2 MSN synapses was mediated by the retrograde 
signaling eCB. As shown in Figure 2, A–D, both the reduction in 
the amplitude of eEPSCs and the increase in PPR in D1 MSNs fol-
lowing LTD induction are comparable between WT and Shank3B-
KO mice. However, in response to the same HFS/DP stimulation 
paradigm, the activity-dependent reduction of eEPSC amplitude 
in Shank3B-KO D2 MSNs was significantly less when compared 
with D2 MSNs in WT mice (Figure 2, E–G, eEPSC amplitude in the 
last 10 minutes relative to baseline). Consistently, the increase in 
PPR (50 ms of interpulse interval) of eEPSCs following the high-
frequency stimulation of glutamatergic afferents was not observed 
in D2 MSNs from Shank3B-KO mice (PPR in the last 10 minutes 
relative to baseline, Figure 2H). Together, these data demonstrate 
that the loss of Shank3 selectively impaired LTD in D2 MSNs.
The HFS/DP striatal LTD induction requires the coactivation 
of postsynaptic Cav1.3 L-type calcium channels and the predomi-
nant group I mGluRs in striatum, type 5 metabotropic glutamate 
receptors (mGluR5) in MSNs, which leads to a robust elevation 
in dendritic Ca2+ levels (55, 57, 64, 65). This activity-induced 
elevation in dendritic Ca2+ levels then triggers the production of 
eCB, which acts on presynaptic CB1Rs. The CB1R, a Gi/o-cou-
pled receptor, is known to inhibit glutamate release when acti-
vated. Thus, striatal LTD induction originates from postsynaptic 
sites, but expresses through a presynaptic mechanism involving 
a decrease in glutamate release probability via retrograde eCB 
signaling. We thus tested whether Shank3 disruption specifically 
affected mGluR5 activity and Cav1.3 activity, thereby contributing 
to impaired HFS/DP-LTD in D2 MSNs.
We first induced corticostriatal eCB-LTD by pharmacologi-
cal activation of group 1 mGluRs (mGluR1 and mGluR5) using the 
selective agonist (R,S)-3,5-dihydroxyphenylglycine (DHPG). We 
observed a robust induction of LTD in WT D2 MSNs following the 
application of 100 μM DHPG for 10 to 15 minutes in the presence 
of NMDA receptor (NMDAR) blocker DL–2-amino-5-phospho-
that expressed either tdTomato in D1R-expressing direct path-
way–projecting MSNs (Drd1a-tdTomato mice) (51) or EGFP in 
D2R-expressing indirect pathway–projecting MSNs (Drd2-EGFP 
mice) (52). Using whole-cell voltage clamp recordings, we mea-
sured AMPAR-mediated miniature excitatory postsynaptic cur-
rents (mEPSCs) in the presence of tetrodotoxin (TTX) and pic-
rotoxin (PTX). We found a reduction of mEPSC peak amplitude 
in both D1 MSNs and D2 MSNs of Shank3B-KO mice. However, 
the frequency of AMPAR-mediated mEPSCs was reduced only in 
D2 MSNs, but not D1 MSNs (Figure 1, A–D). Such distinct gluta-
matergic synaptic transmission changes in D2 MSNs suggest that 
Shank3 loss may lead to a reduced number of synapses, reduced 
presynaptic release probability, or both selectively onto D2 MSNs, 
while leaving D1 MSNs relatively intact. We thus measured paired-
pulse ratio (PPR, 50 ms of interpulse interval) to assess presyn-
aptic release probability. A significant enhancement in PPR was 
found only in D2 MSN recordings in Shank3B-KO mice, indicative 
of reduced presynaptic release probabilities of the glutamatergic 
presynaptic terminals innervating D2 MSNs in Shank3B-KO mice 
(Figure 1, E and F). The selective alteration in presynaptic release 
probability likely contributes, at least partially, to the reduced fre-
quency of mEPSCs observed in D2 MSNs in Shank3B-KO mice.
Another important component that regulates striatal MSN 
activity is the local GABAergic interneuron. Electrophysiological 
studies have demonstrated that striatal MSNs receive prominent 
GABAergic innervations. Moreover, these striatal GABAergic 
interneurons have distinct firing patterns and connections with 
MSNs and thus may exert different effects on D1 and D2 MSNs 
(53, 54). As shown in Supplemental Figure 1 (supplemental mate-
rial available online with this article; https://doi.org/10.1172/
JCI87997DS1), we did not observe significant changes in both 
frequency and peak amplitude of GABAA receptor–mediated min-
iature inhibitory postsynaptic currents (mIPSCs) in D1 and D2 
MSNs of Shank3B-KO mice. In addition, the final output activity 
of MSNs is also determined by intrinsic membrane properties; 
we thus examined and compared the MSN membrane properties 
between Shank3B-KO and WT mice. As shown in Supplemental 
Table 1, we did not observe significant alterations in resting mem-
brane potential, threshold potential, membrane input resistance, 
or rheobase amplitude between Shank3B-KO and WT mice. How-
ever, when we examined the frequency-current (F/I) relationship, 
we found a left shift trend of the averaged F/I curve in D2 MSNs 
of Shank3B-KO mice as compared with D2 MSNs of WT mice. 
Although 2-way ANOVA interaction analysis showed no statisti-
cal significance (Supplemental Figure 2) using Sidak’s multiple 
comparisons test, the firing frequency of D2 MSNs in Shank3B-KO 
mice was significantly higher than in WT D2 MSNs, suggesting an 
increased intrinsic excitability of Shank3B-KO D2 MSNs.
Shank3 deletion selectively impaired endocannabinoid-mediated 
long-term depression in D2 MSNs. Long-lasting changes in syn-
aptic strength at MSN glutamatergic synapses have been impli-
cated in habitual learning and striatal-based cognitive functions. 
The plasticity of the MSN glutamatergic synapses is known to 
be modulated by endocannabinoid (eCB), and eCB-dependent 
long-term depression (eCB-LTD) is one of the most dominant 
forms of long-term plasticity expressed at MSN glutamatergic 
synapses (55–58). eCBs are released by postsynaptic neurons and 
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mice (Figure 3, B and C). Thus, the current density of Cav1.3 chan-
nels in D2 MSNs is selectively affected in Shank3B-KO mice.
A previous study (65) showed that strong activation of L-type 
calcium channels by the agonist FPL64176 was sufficient to induce 
LTD at striatal excitatory synapses (FPL-LTD) and that this type 
of LTD shared a retrograde eCB signaling mechanism with HFS/
DP-LTD. As expected, application of FPL64176 (500 nM) to stria-
tal slices induced robust LTD in WT D1 and D2 MSNs (Figure 3, F 
and I). Similarly, D1 MSNs in Shank3B-KO mice exhibited robust 
FPL-LTD (Figure 3, F–H). In contrast, the same induction proto-
col resulted in impaired LTD in D2 MSNs from Shank3B-KO mice. 
Instead of depression, a late potentiation in some D2 MSNs was 
observed (Figure 3, I–K), indicating an altered calcium concentra-
tion and/or dynamics due to reduced Cav1.3 activity in D2 MSNs 
of Shank3B-KO mice. Furthermore, the increase of PPR of eEPSCs 
following application of FPL was observed only in D2 MSNs from 
WT mice, but not in those from Shank3B-KO mice (Figure 3K). Of 
note, we also observed a trend toward an increase in the decay 
time constant (τw) of the average EPSCs after FPL application in 
about half of the D2 MSNs of Shank3B-KO mice (cells shown as 
LTP instead of LTD; WT-before: 13.5 ± 3.30 ms, WT-after: 15.7 ± 
2.77 ms, n = 6 cells, N = 3 mice. KO-before: 12.7 ± 2.10 ms, KO-
after: 24.83 ± 6.00 ms, n = 7 cells, N = 3 mice; 2-way ANOVA, P = 
novaleric acid (DL-APV) (50 μM) and GABAA receptor antago-
nist PTX (100 μM). However, D2 MSNs from Shank3B-KO mice 
showed a significantly reduced magnitude of DHPG-induced LTD 
(Figure 2, M–P). In contrast, DHPG application induced compara-
ble LTD in D1 MSNs of WT and Shank3B-KO mice (Figure 2, I–L).
MSNs coexpress 2 subclasses of L-type calcium channels, 
referred to as Cav1.2 and Cav1.3, that are characterized by their dis-
tinct pore-forming α subunits α1C and α1D, respectively (66–68). 
Previous studies by Olson et al. (69) demonstrated that the 2 chan-
nels differ in their affinity for dihyhropyridine (DHP) antagonists 
in acutely isolated striatal MSNs. In particular, Olson et al. found 
that a low concentration of nimodipine (1 μM) produces a near 
complete block of Cav1.2 channels in MSNs from Cav1.3-knockout 
mice and that Cav1.3 channel–mediated currents could be opera-
tionally defined as those blocked by 10 μM nimodipine, but not 1 
μM nimodipine. We applied the same method to determine wheth-
er Shank3 deletion could affect Cav1.3 L-type calcium channel 
activity in Shank3B-KO MSNs (Figure 3A). We found that Cav1.3 
channel currents elicited in D2 MSNs of Shank3B-KO mice were 
significantly reduced compared with those of WT mice, but this is 
not the case for Cav1.2 channel–mediated currents (Figure 3, D and 
E). In contrast, in D1 MSNs, neither Cav1.2 nor Cav1.3 channel cur-
rents showed significant differences between WT and Shank3B-KO 
Figure 2. Shank3 deletion selectively impaired LTD in D2 MSNs, but not D1 MSNs. (A, I, E, M) Averaged traces from a representative LTD experiment in 
D1 (A and I) and D2 MSNs (E and M) using HFS-LTD protocol (A and E) and DHPG-LTD protocol (I and M). Light traces represent the baseline EPSC average 
from 0 to 10 minutes (labeled with light color number 1), and dark traces represent the average EPSC from the last 10 minutes after LTD induction (dark 
color number 2). (B, J, F, N) LTD is similar between WT and KO D1 MSNs in both HFS-LTD (B) and DHPG-LTD (J). KO D2 MSNs show less reduction level 
compared with WT D2 MSNs in both HFS-LTD (F) and DHPG-LTD (N). (C, G, K, O) Summary data of eEPSC amplitudes of D1 MSNs (C and K) and D2 MSNs 
(G and O) from WT and KO mice using the HFS-LTD protocol (C and G) and the DHPG-LTD protocol (K and O) (comparison between baseline and the last 10 
minutes of recording). C, D1 MSNs, WT, n = 8, N = 3; KO, n = 6, N = 3, P = 0.89; G, D2 MSNs: WT, n = 11, N = 6; KO, n = 11, N = 6, P = 0.0165; K, D1 MSNs: WT, 
n = 6, N = 2; KO, n = 6, N = 2, P = 0.95: O, D2 MSNs: WT, n = 7, N = 3; KO, n = 8, N = 3, P = 0.0104. (D, H, L, P) Summary data of PPR of D1 MSNs (D and L) 
and D2 MSNs (H and P) from WT and KO mice using the HFS-LTD protocol (D and H) and the DHPG-LTD protocol (L and P) (last 10 minutes PPR relative to 
baseline). D, D1 MSNs: WT and KO, P = 0.15; H, D2 MSNs: WT and KO, P = 0.0002; L, D1 MSNs: WT and KO, P = 0.36; P, D2 MSNs: WT and KO, P = 0.0072. 
An unpaired t test was used for comparisons. *P < 0.05; **P < 0.01; ***P < 0.001. n, cell number; N, animal number.
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0.1795, Supplemental Figure 4). While the reason for the 
slower decay kinetic is still unclear, a possible explanation 
for the LTP in the subgroup of D2 MSNs of Shank3B-KO 
mice might be an increase in the expression of GluR2-lack-
ing AMPARs at the synaptic sites (70–72), where a reduc-
tion of GluR2 proteins in the PSD of Shank3B-KO mice was 
observed in our previous study (31). Together, these data 
demonstrate a striatal D2 MSN–specific plasticity defect in 
Shank3B-KO mice.
Because of the postsynaptic localization of SHANK3 
protein, the defective striatal LTD in D2 MSNs of Shank3B-
KO mice most likely has a postsynaptic origin, consistent 
with the upstream signaling pathways required for eCB gen-
eration. However, it is possible that deletion of Shank3 may 
directly affect presynaptic CB1R function. Thus, we specifi-
cally investigated whether signaling via presynaptic CB1Rs 
was altered in Shank3B-KO D2 MSNs by directly activating 
CB1Rs with WIN 55212-2 (1 μM), a CB1R-specific agonist. 
We found that application of WIN-55212-2 at a concentra-
tion eliciting submaximal levels of synaptic depression 
resulted in a similar reduction of eEPSC amplitude in D2 
MSNS of WT and Shank3B-KO mice (Supplemental Figure 
5, A and B). Consistent with its effect on presynaptic release 
properties, WIN 55212-2 also similarly increased the PPR 
ratio in WT and Shank3B-KO D2 MSNs (Supplemental Fig-
ure 5C). These results suggest that there are no significant 
alterations in CB1R-mediated signaling itself in Shank3B-
KO D2 MSNs and that the changes found in striatal LTD are 
most likely due to the altered eCB signaling activity origi-
nating from the postsynaptic side.
D2 MSNs are more vulnerable to structural alterations 
upon Shank3 deletion. Shank3 gene mutations identified in 
autism have been found to affect dendritic spine develop-
ment and morphology through an actin-dependent mecha-
nism (73–76). Our previous studies found reduced spine 
Figure 3. Shank3 deletion selectively impaired Cav1.3 function in 
D2 MSNs, but not D1 MSNs. (A) Protocol used to separate Cav1.2- 
and Cav1.3-mediated current. (B and D) Representative recordings 
of Cav1.2 and Cav1.3 in WT and KO D1 MSNs (B) and D2 MSNs (D). 
(C and E) Cav1.3 channel current density was only reduced in KO D2 
MSNs (C, left: D1 current density, Cav1.2: WT, n = 7, N = 2; KO, n = 7, 
N = 2, P = 0.69; Cav1.3: WT, n = 7, N = 2; KO, n = 7, N = 2, P = 0.89; C, 
right: D1 half-activation voltage (Vmid) Cav1.2: WT and KO, P = 0.62; 
Cav1.3: WT and KO, P = 1.0; E, left: D2 current density, Cav1.2: WT,  
n = 9, N = 2; KO, n = 9, N = 2, P = 0.61; Cav1.3: WT, n = 9, N = 2; KO,  
n = 9, N = 2, P = 0.0395; E, right: D2 Vmid, Cav1.2: WT and KO,  
P = 0.44; Cav1.3: WT and KO, P = 0.30). (F and I) Time course plots 
of FPL64176-LTD and representative traces of WT and Shank3B KO 
D1 MSNs (F) and D2 MSNs (I) after FPL64176 bath perfusion. KO D2 
MSNs showed impaired FPL64176-induced LTD. (G and J) Summary 
data of eEPSC amplitudes (Amp.) of D1 MSNs (G) and D2 MSNs (J) 
from WT and KO mice (last 10 minutes eEPSC amplitude relative 
to baseline; G, D1 MSNs: WT, n = 8, N = 6. KO, n = 7, N = 4, P = 0.31. 
J, D2 MSNs: WT, n = 5, N = 3; KO, n = 7, N = 3, P = 0.0064). (H and K) 
Summary data of PPR of D1 MSNs (H) and D2 MSNs (K) from WT 
and Shank3B-KO mice (last 10 minutes PPR relative to baseline; H, 
D1 MSNs: WT and KO, P = 0.29. K, D2 MSNs: WT and KO, n = 7;  
P = 0.040). An unpaired t test was used for comparisons. *P < 0.05; 
**P < 0.01. n, cell number; N, animal number.
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density in MSNs of Shank3B-KO mice. Here, we examined whether 
Shank3 deletion differentially affected spine density in D1 MSNs 
versus D2 MSNs. We applied a modified viral-based method to 
sparsely label striatal neurons using a membrane-targeted EGFP 
(EGFPf) delivered with an AAV viral vector (AAV-hSyn1-EGFPf-
WPRE-hGH), which could pass the blood-brain barrier to infect 
neurons when injected into the retroorbital venous sinus (77). We 
injected AAV-hSyn1-EGFPf-WPRE-hGH into 2- to 4-month-old 
Shank3B-KO/Drd1a-tdTomato and WT/Drd1a-tdTomato mice 
and imaged MSNs (Supplemental Figure 6). We quantified the 
total and mushroom-shaped spine density of both D1 (tdTomato 
positive) and D2 (tdTomato negative) MSNs in the dorsal striatum 
of WT and Shank3B-KO mice. We found that both the total and 
mushroom-shape spine density in D2 MSNs of Shank3B-KO mice 
were significantly reduced compared with those of WT mice (Fig-
ure 4, B and D), whereas only a trend of reduction was observed 
in D1 MSNs of Shank3B-KO mice (Figure 4, A and C). In addition, 
we traced striatal D1 versus D2 MSNs to investigate the cellular 
morphology and dendritic complexity of these cells in both WT 
and Shank3B-KO mice. Sholl analysis revealed a reduced dendritic 
complexity in D2 MSNs of Shank3B-KO mice as compared with WT 
mice. Again, D1 MSNs of KO mice showed levels of dendritic com-
plexity comparable to those of WT mice (Supplemental Figure 7).
Enhancing the activity of D2 MSNs, but not D1 MSNs, rescued 
repetitive grooming behavior in Shank3B-KO mice. Our above results 
suggest that Shank3 deletion leads to more prominent synaptic 
defects in D2 MSNs. Since coordinated and balanced activity of the 
direct and indirect pathways is critical for normal striatum–medi-
ated actions (47, 78, 79), we set out to test whether D2 MSN dysfunc-
tion plays a causative role in repetitive grooming behavior observed 
in Shank3B-KO mice. To enhance the activity of D2 MSNs, we used 
the stimulatory designer receptors exclusively activated by designer 
drugs (DREADD-hM3Dq, where hM3Dq indicates Gq-coupled 
human M3 muscarinic receptor), which couples through a Gq path-
way to depolarize neuronal membrane potential upon the appli-
cation of synthetic ligand clozapine-N-oxide (CNO) (80–82). We 
bilaterally injected the Cre-dependent AAV8-hSyn-DIO-hM3Dq-
mCherry (hM3Dq-mCherry) into the dorsal striatum of WT/Drd1a-
Cre, Shank3B-KO/Drd1a-Cre, WT/A2a-Cre, and Shank3B-KO/A2a-
Cre mice to selectively express hM3Dq-mCherry in D1 or D2 MSNs. 
As shown in Figure 5A, mCherry was specifically detected in dorsal 
striatal MSNs with no expression in other brain regions. In parallel, 
all control mice shown in Figure 5 had received bilateral injections 
of AAV8-hSyn-DIO-mCherry targeting the dorsal striatum. To test 
the functionality of DREADD-hM3Dq in MSNs, we performed 
whole-cell current clamp recordings of hM3Dq-mCherry–posi-
tive MSNs in acute brain slices. We found that hM3Dq-mCherry–
expressing MSNs, but not control hSyn-mCherry–expressing cells, 
exhibited an increased excitability upon local application of CNO, 
as evidenced by a marked membrane depolarization and increased 
firing rate in hM3Dq-mCherry–positive MSNs (Figure 5B).
We next examined whether enhancing the activity of D2 
MSNs by DREADD-hM3Dq could rescue repetitive grooming 
behavior in Shank3B-KO mice. Because strong activation of D2 
MSNs can lead to motor inhibition, as demonstrated by the opto-
genetic activation study (83), and thus confound our behavioral 
analysis, we tested the effect of different doses of CNO on motor 
activity in WT/A2a-Cre and Shank3B-KO/A2a-Cre mice injected 
with AAV8-hSyn-DIO-hM3Dq-mCherry. We found that admin-
istration of CNO at concentrations of 0.7 mg/kg or 1.0 mg/kg, 
commonly used doses in mice, caused significant inhibition of 
motor activity (Supplemental Figure 8). Conversely, administra-
tion of CNO at a concentration of 0.7 mg/kg or 1.0 mg/kg (data 
not shown) to WT/Drd1a-Cre and Shank3B-KO/Drd1a-Cre mice 
injected with AAV8-hSyn-DIO-hM3Dq-mCherry dramatically 
increased motor activity (Supplemental Figure 8). We thus used 
a lower dose of CNO (0.3 mg/kg body weight) for our behavioral 
experiments, aiming to correct the reduced activity of D2 MSNs 
in Shank3B-KO mice without inducing significant motor activity 
changes. We found that administration of CNO at a concentration 
of 0.3 mg/kg to Shank3B-KO/A2a-Cre mice injected with AAV8-
hSyn-DIO-hM3Dq-mCherry significantly reduced self-grooming 
Figure 4. Reduced spine density in D2 MSNs of Shank3B-KO mice. (A and B) Representative spine images of D1 (A) and D2 (B) MSNs from WT and KO 
MSNs. Scale bar: 5 μm. (C and D) Bar graphs summarizing total spine density and mushroom-shaped spine density of WT and KO MSNs. (C) D1 MSNs, total 
spine density: WT and KO, n = 18, P = 0.06. Mushroom-shaped spine density: WT and KO, n = 18, P = 0.19. (D) D2 MSNs, total spine density: WT and KO, 
n = 16, P = 0.0052. Mushroom-shaped spine density: WT and KO, n = 16, P = 0.01. An unpaired t test was used for comparisons. *P < 0.05; **P < 0.01. n, 
dendritic segments number.
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Figure 5. Enhancing D2 MSN activity using DREADD-hM3Dq reduced repetitive grooming behavior in Shank3B-KO mice. (A) The injecting site of AAV-
DIO-hM3Dq-mCherry virus and behavior paradigm. (B) Representative traces of CNO-induced neuronal membrane depolarization of a hM3Dq-mCherry- 
expressing D1 (upper panel) or D2 MSN (lower panel). (C and E) A reduction in grooming time between pre- and post-CNO treatment only was found in KO/
A2a-Cre mice. (C, D1: WT-mCherry, N = 7, P = 0.78; KO-mCherry, N = 6, P = 0.88; WT-hM3Dq, N = 7, P = 0.54; KO-hM3Dq, N = 7, P = 0.87; E, D2: WT-mCherry, 
N = 6, P = 0.75; KO-mCherry, N = 6, P = 0.75; WT-hM3Dq, N = 7, P = 0.18; KO-hM3Dq, N = 7, P = 0.0031). (D and F) DREADD significantly decreased grooming 
changes in KO/A2a-Cre mice (F, WT and KO, P = 0.43. mCherry and DREADD, P = 0.03; interaction, P = 0.29, 2-way ANOVA), but not D1-Cre mice (D, WT and 
KO, P = 0.9. mCherry and DREADD, P = 0.78; interaction, P = 0.78). (G and I) Summary data showing no changes in locomotor activity between pre- and post-
CNO treatment in WT/D1-Cre or KO/D1-Cre mice (G, WT-mCherry, N = 6, P = 0.33; KO-mCherry, N = 6, P = 0.89; WT-hM3Dq, N = 6, P = 0.18; KO-hM3Dq, N = 6, 
P = 0.08.) and WT/A2a-Cre or KO/A2a-Cre mice (I, WT-mCherry, N = 7, P = 0.10; KO-mCherry, N = 6, P = 0.07; WT-hM3Dq, N = 7, P = 0.41; KO-hM3Dq, N = 9,  
P = 0.29). (H and J) DREADD did not change locomotor activities in both D1-Cre mice (H, WT and KO, P = 0.18. mCherry and DREADD, P = 0.66; interaction,  
P = 0.05) and A2a-Cre mice (J, WT and KO, P = 0.64. mCherry and DREADD, P = 0.81; interaction, P = 0.57). A paired t test was used for C, E, G, and I and 
2-way ANOVA was used for D, F, H, and J. *P < 0.05; **P < 0.01. N, animal number.
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tive behaviors other than self-grooming. However, the high lev-
els of anxiety and locomotion defects in Shank3B mutant mice 
complicate other repetitive behavior tests such as marble bury-
ing (data not shown). Future studies with other ASD models will 
be needed to address this question.
Currently, the molecular mechanisms of how Shank3 loss 
causes the differential structural and functional alterations 
between D1 MSNs and D2 MSNs are unknown. Although Shank3 
is expressed in both D1 MSNs and D2 MSNs (69), D1 MSNs and D2 
MSNs have differential transcriptome profiles, including differen-
tial expression of many signaling proteins (87, 88). Therefore, since 
SHANK3 is a major scaffolding protein, one possible explana-
tion is that SHANK3-containing scaffolds form distinct signaling 
complexes in D1 MSNs and D2 MSNs and that disruption of these 
complexes may lead to distinct synaptic defects. Alternatively, 
the Shank3 gene has multiple intragenic promoters and extensive 
alternative splicing, thereby producing multiple isoforms in the 
mouse brain (33, 75, 89). These different isoforms may be differ-
entially expressed in D1 MSNs and D2 MSNs. Based on the pres-
ence of unique protein-binding domains in each isoform, distinct 
signaling complexes could form and thus result in distinct defects 
in the 2 types of MSNs. Recent work from Wang et al. (75) pro-
vides direct evidence demonstrating that Shank3 isoforms display 
different subcellular localization and differential effects on den-
dritic and spine morphology, further supporting this hypothesis. 
Thus, it is tempting to speculate that deletion of Shank3 leads to 
the disruption of distinct synaptic signaling complexes in D1 and 
D2 MSNs due to differential binding partners in these 2 types of 
cells. The disruption of SHANK3 signaling in D2 MSN affects both 
pre- and postsynaptic function, while Shank3 deletion in D1 MSNs 
only causes a postsynaptic change of reduced synaptic AMPAR 
response. In addition, reduced neuronal dendritic complexity is 
only found in D2 MSNs. The reduced dendritic complexity result 
appeared to be inconsistent with our previous report, where a 
hypertrophy of striatal neuronal morphology was found in Shank3 
mutant mice (31). While we don’t know the exact reasons for the 
seemingly inconsistent dendritic complexity results, our previ-
ous study was done on 5-week-old mice, whereas 3- to 5-month-
old mice were used in the current study. In addition, in our prior 
study, we collected a mixed population of both D1 and D2 MSNs. 
Considering the intrinsically different dendritic structures with 
higher dendritic complexity in D1 MSNs than in D2 MSNs (shown 
in Supplemental Figure 7), a confounding effect from the MSN 
cell types other than genotype might also contribute to the dis-
crepancy. It will be important to directly test the functional roles 
of Shank3 isoforms at specific synapses and in different cell types 
during development and to assess the relevance of the difference 
isoforms to the neural circuit dysfunction that underlies autistic-
like behaviors.
Defects of mGluR5 signaling have been found in several 
mouse models of ASD (90–92). SHANK3 is known to interact with 
mGluR5 via the Homer adaptor protein. Given the fact that eCB 
generation requires the activation of postsynaptic calcium signal-
ing and mGluR5, it is not surprising that we found defects in eCB-
mediated long-term synaptic plasticity in D2 MSNs of Shank3B-
KO mice. While both Shank3B-KO mice and the Tsc2+/– mouse 
model of tuberous sclerosis complex exhibited a reduction in 
(Figure 5, E and F) without significantly affecting motor activity 
(Figure 5, I and J). On the other hand, enhancing the activity of 
D1 MSNs by CNO in Shank3B-KO/Drd1a-Cre mice injected with 
AAV8-hSyn-DIO-hM3Dq-mCherry did not affect self-grooming 
behavior (Figure 5, C and D); instead, the mice showed a trend of 
increased motor activity (Figure 5, G and H). Thus, enhancing D2 
MSN activity, but not D1 MSN activity, is sufficient to correct the 
repetitive grooming behavior in Shank3B-KO mice.
Finally, we tested whether reducing D2 MSN activity in WT 
mice may increase repetitive grooming. To reduce the activity of 
D2 MSNs, we used the inhibitory DREADD (DREADD-hM4Di), 
which couples through a Gi pathway to hyperpolarize neuronal 
membrane potential upon the application of CNO. We bilater-
ally injected Cre-dependent AAV8-hSyn-DIO-hM4Di-mCherry 
(hM4Di-mCherry) into the dorsal striatum of WT/A2a-Cre mice 
to selectively express hM4Di-mCherry in D2 MSNs. To test the 
functionality of DREADD-hM4Di in MSNs, we performed whole-
cell current clamp recordings of hM4Di-mCherry–positive MSNs 
in acute brain slices. We found that hM4Di-mCherry–expressing 
MSNs exhibited a hyperpolarization upon local application of 
CNO (Supplemental Figure 9, A and B). We then tested the effect 
of CNO (0.3 mg/kg) on repetitive grooming behavior of WT/A2a-
Cre mice bilaterally injected with hM4Di-mCherry. In parallel, all 
control WT/A2a-Cre mice (without hM4Di-mCherry viral injec-
tion) were treated with the same dosage of CNO and tested for 
grooming duration. As shown in Supplemental Figure 9C, no sig-
nificant changes in grooming duration were observed between the 
2 groups. Although these results suggest that a moderate reduction 
in D2 MSN activity alone could not induce repetitive grooming in 
WT mice, other explanations also exist. First, rescuing behavioral 
defects may only require the normalization of a subset of neurons 
in the circuit, while generating behavioral defects may require a 
larger subset of abnormally functioning neurons. Second, there 
might be some compensatory mechanisms that could regain a 
balanced activity of the 2 striatal pathways in WT mice, whereas 
in Shank3B-KO mice, such compensatory mechanisms might be 
compromised and imbalanced activity of the 2 striatal pathways 
could eventually lead to the repetitive grooming behavior.
Discussion
In the present work, we found synaptic defects in both D1 MSNs 
and D2 MSNs in Shank3B-KO mice. However, Shank3 deletion 
seems to preferentially affect synapses in D2 MSNs, includ-
ing changes in presynaptic and postsynaptic function as well as 
spine density. In D1 MSNs, Shank3 deletion only reduces post-
synaptic AMPAR response. To the best of our knowledge, this is 
the first study to provide direct evidence that a primary dysfunc-
tion in the striatal indirect pathway could give rise to repetitive 
behavior in a mouse model of autism. Previous studies have sug-
gested that an imbalance of the direct and indirect pathways of 
the basal ganglia may underlie repetitive behavior (78, 79, 84). 
Recently, it was shown in neuroligin-1 and neuroligin-3 mutant 
mice that abnormality of D1 MSNs can lead to autistic-like 
behaviors, including repetitive behavior (85, 86). Our present 
study in Shank3B mutant mice demonstrates that hypoactivity 
of D2 MSNs is also sufficient. It will be interesting to determine 
whether modulating D2 MSN activity could also correct repeti-
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way induced repetitive behavior (97–100). However, a potential 
complication for such interpretation is the widespread expression 
of dopamine receptors outside the striatum, such as in the cortex 
and limbic regions (96). Unlike the complexity of pharmacological 
and genetic modulation through dopaminergic receptors, the stria-
tal cell-type–specific activation of direct pathway D1 MSNs either 
by optogenetic or the chemical-genetic DREADD approach did not 
appear to induce repetitive or stereotyped behavior (82, 83, 101), 
which is in agreement with earlier works suggesting that activating 
the direct pathway leads to hyperactivity, not stereotypy (102, 103). 
Overall, our studies highlight the importance of dissecting the 
unique functional role of each pathway individually as well as the 
interplay between the two in order to understand the mechanisms 
underlying repetitive behaviors seen in many psychiatric disorders.
Methods
Animals. The generation of Shank3B-KO mice was described previ-
ously (31). Experimental mice were the progeny of Shank3B+/–/Drd1a-
tdTomato or Drd2-EGFP breeding pairs (with C57BL/6 genetic back-
ground, backcrossing for at least 10 generations) in which only 1 of the 
parents expressed the Drd1a-tdTomato or Drd2-EGFP transgenes, so 
that no experimental subjects were homozygous for the transgenic 
fluorescent markers (51, 52). In experiments testing genotype effects, 
littermate control animals of both sexes were used (age around 1.5 to 
2 months). All experiments were performed and analyzed with the 
experimenter blinded to genotypes.
Electrophysiological studies. Six- to eight-week-old mice of both 
sexes were used for all whole-cell electrophysiology procedures. 
Acute coronal brain slices were prepared as follows. Mice were anes-
thetized with Avertin solution (20 mg/ml, 0.5 mg/g body weight) 
and transcardially perfused with 15 to 20 ml of ice-cold carboge-
nated (95% O2, 5% CO2) cutting solution containing the following: 
194 mM sucrose, 30 mM NaCl, 4.5 mM KCl, 1.2 mM NaH2PO4, 0.2 
mM CaCl2, 2 mM MgCl2, 26 mM NaHCO3, and 10 mM D-(+)-glucose 
(with osmolarity of 340–350 mOsm). The brains were then rapidly 
removed and placed in ice-cold cutting solution for slice preparation. 
Coronal slices (300 μm) were prepared and then incubated at 32°C 
with carbogenated artificial cerebral spinal fluid (aCSF) for 10 to 15 
minutes. The slices were then incubated at room temperature for 
at least 1 hour in aCSF that contained the following: 119 mM NaCl, 
2.3 mM KCl, 1.0 mM NaH2PO4, 26 mM NaHCO3, 11 mM glucose, 1.3 
mM MgSO4, and 2.5 mM CaCl2 (pH 7.4, with osmolarity of 295–305 
mOsm) at room temperature for at least 1 hour.
The slices were constantly perfused with carbogenated aCSF 
at room temperature (22–24°C) for all the spontaneous synaptic 
activity measurements to gain better stability of the patch mem-
brane. For all the plasticity recordings (including HFS induction 
protocol, DHPG, and FPL chemical induction protocol), the slices 
were perfused with carbogenated aCSF at 32°C. The perfusion rate 
was around 3.0 ml/min. The individual fluorescently positive D1 or 
D2 MSNs were identified with a microscope equipped with GFP or 
RFP filter (BX-51WI, Olympus). Whole-cell patch-clamp recordings 
were performed with an IR-DIC visual guide. For AMPA mEPSCs 
and evoked AMPAR-mediated EPSCs, pipettes were filled with the 
internal solution containing the following: 110 CsOH (50% wt), 
d-gluconic acid (49%–53% wt), 4 mM NaCl, 15 mM KCl, 5 mM TEA-
Cl, 20 mM HEPES, 0.2 mM EGTA, 5 mM lidocaine N-ethyl chloride, 
mGluR-induced LTD, the fragile X syndrome (FXS) mouse model 
(Fmr1-KO mice) showed excessive group I mGluR activation, lead-
ing to an increased mGluR-induced LTD (90, 93). Although it is 
not clear whether and how the observed changes in striatal LTD 
in Shank3B-KO mice are linked to autistic-like behaviors such as 
repetitive grooming and social interaction deficits, our results 
further support the notion that mGluR5 signaling abnormalities 
might be a common phenomenon in a subset of ASD models (92). 
In addition, the loss of eCB-LTD could be due to abnormal eCB 
signaling in the Shank3B mutant mice that occludes induction of 
further LTD. It is well established that eCB-LTD can be develop-
mentally regulated. Considering the very recent work that demon-
strated an early hyperactivity of corticostriatal circuits in Shank3B-
KO mice (94), it is possible that a type of abnormal eCB signaling 
has formed during development. It thus will be interesting for our 
future studies to explore the potential abnormal eCB signaling in 
development in Shank3B-KO mice.
One prominent hypothesis posits that repetitive behavior is 
a consequence of relative hyperactivity along cortico–basal gan-
glia–cortical feedback circuits, implicating an imbalanced activity 
between the 2 striatal pathways in the basal ganglia, which even-
tually facilitate the release of compulsive motor programs (84, 95, 
96). Our findings, in particular the correction of repetitive groom-
ing by enhancing D2 MSN activity with the DREADD system in an 
attempt to regain balanced activity between the 2 striatal pathways 
in Shank3B-KO mice, largely support such an activity-imbalance 
theory. However, it is worth noting that the moderate enhancement 
of D1 MSN activity with the DREADD system by applying low-dose 
CNO (0.3 mg/kg) did not induce or exacerbate repetitive groom-
ing behavior in either WT or Shank3B-KO mice (Figure 5, C and D). 
Instead, it only induced a trend of motor activity enhancement in 
Shank3B-KO mice, but not in WT mice (Figure 5, G and H). One 
possible explanation is that Shank3B-KO mice might be more sen-
sitive to such moderate manipulation than WT mice due to their 
disrupted dual-pathway balanced activity toward a relative higher 
activity of direct pathway. Interestingly, such moderate enhance-
ment of indirect pathway activity did not lead to differential chang-
es in motor activity between WT and Shank3B-KO mice (Figure 5, I 
and J). Instead, we only observed the rescue of repetitive grooming 
behavior in Shank3B-KO mice (Figure 5, E and F). Thus, our results 
suggest a much more complex scenario than the simple activity 
imbalance hypothesis. It is possible that, besides the importance of 
balanced and cooperative activity of the 2 striatal pathways, indi-
rect pathway activity might be more engaged in the mediation of 
repetitive behavior, while changes in direct pathway activity might 
have a stronger effect on locomotor activity. Indeed, as shown by 
optogenetic manipulations (83) of MSN activities, bilateral activa-
tion of direct-pathway MSNs elicited an increase in ambulation and 
reduction of fine movements, but changes in such movements were 
not correlated with changes in grooming frequency. Such pathway-
specific engaging function could also explain the distinct rescue of 
locomotion defects when D1 MSN activity, but not D2 MSN activity, 
is enhanced in Shank3B-KO mice (Supplemental Figure 8, C and E) 
when they are given high doses of CNO (0.7 mg/kg).
Previous pharmacological studies and genetic modulation of 
dopaminergic genes (such as the dopamine transporter DAT and 
the D1 receptor) indicated that enhanced activity of the direct path-
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total thickness of approximately 100 μm. Each neuron was manually 
traced by using Neurolucida software (MBF Bioscience) for 3D recon-
struction and measurements. Stack images (1024 × 1024 pixels) of 
spines were acquired using a 60× oil lens plus 6× zoom-in. Huygens 
Deconvolution software (Scientific Volume Imaging) was used to pro-
cess the images. Spines for the imaged dendritic segments were auto-
matically detected and grouped into mushroom and nonmushroom 
using NeuronStudio software (CNIC) with a post-hoc manual correc-
tion. Experimenters were blinded to genotypes of mice during viral 
injection, imaging, and measurement analyses.
Viral injections for DREADD-hM3Dq rescue experiments. Each 
mouse was deeply anesthetized (1%–2% isoflurane) and was admin-
istered a dose of 1 mg/kg of meloxicam subcutaneously by injection 
prior to any incisions being made. The mouse was then mounted in 
a stereotaxic frame with nonpuncturing ear bars. AAV8-hSyn-DIO-
hM3Dq-mCherry or control AAV8-hSyn-DIO-mCherry (University 
of North Carolina Viral Vector Core, Chapel Hill, North Carolina, 
USA; approximate titer 2 × 1012 GC/ml) solution was injected using a 
nanoinjector with injection micropipette at the following coordinates 
for each mouse: anterior/posterior: 1.18 mm, medial/lateral: ±1.25 
mm, dorsal/ventral: 2.2 mm and 2.8 mm; anterior/posterior: 1.18 mm, 
medial/lateral: ±1.8 mm, dorsal/ventral: 2.2 mm and 3.0 mm; ante-
rior/posterior: 0.35 mm, medial/lateral: ±1.5 mm, dorsal/ventral: 2.4 
mm and 3.0 mm; anterior/posterior: 0.35 mm, medial/lateral: ±2.2 
mm, dorsal/ventral: 2.4 mm, 3.0 mm and 3.5 mm. A total volume of 
69 nl was injected at each desired depth at the speed of 23 nl per sec-
ond. Incisions in the scalp were closed after injection, and animals 
were allowed to recover in accordance with MIT Committee on Ani-
mal Care guidelines. After surgery, mice were individually housed for 
2 weeks before behavioral tests.
Behavioral experiments. Grooming behavior was measured as pre-
viously described (31). Briefly, mouse grooming was videotaped and 
coded from 19:00 to 21:00 hours beginning at the initiation of the dark 
cycle; this segment was analyzed using Noldus Observer software, and 
the total amount of time in the 2-hour segment spent grooming was 
determined. Grooming included all sequences of face wiping, scratch-
ing/rubbing of head and ears, and full-body grooming. Locomotion 
activity was measured using LABORAS (Metris), which relies on vibra-
tion and force signal analysis to determine both the behavior and the 
position of the animal (105). Three hours of continuous recordings 
were classified with LABORAS software v2.5 to establish locomotion 
activity. To test the effect of CNO on locomotion activity and groom-
ing behavior, mice were placed in the chamber of LABORAS for 1 
hour for habituation and 1 hour recording for basal behavior. Then the 
mice were injected with a dose of CNO and returned to the LABORAS 
chamber for another 2 hours of recording. The observer was blinded to 
genotypes during the scoring of the videotapes.
Drugs. TTX, PTX, NBQX, and DHPG were purchased from 
Tocris. DL-APV, WIN55,212-2 mesylate salt, and FPL64176 were 
purchased from Sigma-Aldrich. All drugs were made as concentrated 
stock solutions and diluted in aCSF to their final concentration on the 
experiment day and delivered with constant perfusion to the record-
ing chamber. For drug stocks prepared with DMSO, the final DMSO 
concentration was less than 0.1%.
CNO was purchased from Sigma-Aldrich. For experiments in 
mice, CNO was first dissolved in DMSO and then diluted to a final 
concentration with saline. The final concentration of DMSO was 
4 mM ATP magnesium salt, and 0.3 mM GTP sodium salt. pH was 
adjusted to 7.2–7.4 with CsOH, and osmolarity was adjusted to 298–
300 mOsm with K2SO4 (approximately 8–10 mM). For GABAA recep-
tor–mediated mIPSCs, pipettes were filled with internal solution 
containing the following: 103 mM CsCl, 12 mM CsOH (50% wt), 
12 mM methanesulfonic acid, 4 mM NaCl, 5 mM TEA-Cl, 10 mM 
HEPES, 0.5 mM EGTA, 10 mM phosphocreatine, 5 mM lidocaine 
N-ethyl chloride, 4 mM ATP magnesium salt, and 0.3 mM GTP 
sodium salt. pH was adjusted to 7.2–7.4 with KOH, and osmolarity 
was adjusted to 298–300 mOsm with K2SO4 (approximately 8–10 
mM). Miniature synaptic events were not recorded until 5 minutes 
after entering whole-cell patch-clamp recording mode to allow the 
dialysis of Cs+ internal solution for a relatively complete block of the 
potassium channels in the striatal MSNs. Cells in which the series 
resistance (Rs, typically 8–12 MΩ) changed by more than 20% were 
excluded for data analysis. In addition, cells with Rs of more than 
20 MΩ at any time during the recordings were discarded. Cell mem-
brane potential was held at –70 mV unless otherwise specified, with 
a Multiclamp 700B amplifier (Molecular Devices). Signals were 
low-pass filtered at 2 kHz and sampled at 10 kHz with a Digidata 
1440A (Molecular Devices), and data were stored on a computer for 
subsequent off-line analysis. mEPSCs and mIPSCs were detected 
and analyzed with MiniAnalysis (Synaptosoft).
For paired-pulse stimulation experiments and LTD experiments, 
AMPAR-mediated EPSCs were evoked by a local concentric bipolar 
stimulating electrode (CBARC75, FHC). The stimulating electrode 
was placed in the inner edge of the corpus callosum within the dorso-
lateral striatum. Recordings were made in the presence of PTX (100 
μM) and DL-APV (50 μM) to block activation of GABAA receptors and 
NMDARs. The stimulus intensity was set at a level that evoked 200–
300 pA of AMPAR-mediated EPSCs for all the cells measured and 
delivered with an interstimulus interval of 50 ms. Paired-pulse mea-
surements were obtained for 15 consecutive traces, and only those 
traces with stable evoked first current response were used for data 
analysis. The PPR was calculated with the peak current response to 
the second pulse divided by that of the first response. Only those 
neurons present in the baseline drifting less than 10% over 30 min-
utes were used to induce LTD protocol for either HFS or chemical 
LTD experiments.
Morphological characterization of dendritic trees and spines. To 
sparsely label MSNs, 25 μl pAAV-hSyn1-EGFPf-WPRE-hGH virus 
(Penn Vector Core, University of Pennsylvania, Philadelphia, Pennsyl-
vania, USA) with the titer of 2 × 1012 (GC/ml) in PBS was delivered into 
mouse blood circulation through retroorbital injection of the venous 
sinus (104). Shank3B-KO/Drd1a-tdTomato mice and WT littermates 
were injected with virus at the age of 2 to 4 months and euthanized 
3 weeks later for immunostaining. PFA-fixed 200-μm–thick coronal 
brain slices were prepared using Vibratome. Immunostaining was 
performed with an anti-GFP antibody (Invitrogen, catalog A11122) to 
visualize EGFPf expression. After staining, each slice was surrounded 
by a 240-μm depth spacer (Electron Microscopy Sciences) and mount-
ed on slides with nonhardening Vectashield mounting medium (Vec-
tor Laboratories, catalog H-1000).
Olympus Fluoview FV1000 confocal microscope was used to 
image EGFP-labeled dorsal striatal MSN cells. To acquire relatively 
intact dendritic trees, neurons located around the center in the depth 
of sections were imaged under a 40× oil lens at 1-μm intervals for a 
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important intellectual content. CRG provided Drd1a-Cre mice. 
ZF wrote the manuscript with input from WW, C Li, and GF.
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